Scoping Review on SGLT2 Inhibitors for IgA Nephropathy: Efficacy and Outcomes

A 684.8 KB scoping review document by Atthaphong Phongphithakchai, last updated on 2026-04-30. It maps evidence from two large randomized controlled trials (DAPA-CKD and EMPA-KIDNEY) and complementary observational studies on the effects of SGLT2 inhibitors in patients with IgA nephropathy. The review was conducted according to PRISMA-ScR guidance and is registered under CRD42025630522.

Use Cases

• Summarizing randomized and observational evidence on SGLT2 inhibitor efficacy based on the described outcome domains.
• Identifying research gaps for future IgA nephropathy studies based on the review's conclusions.
• Contextualizing mechanistic patterns linking hemodynamic responses to renal benefit as discussed in the results.

Strengths

• Follows PRISMA-ScR guidance for scoping reviews, a structured methodological standard.
• Synthesizes evidence from two named large randomized trials (DAPA-CKD, EMPA-KIDNEY) and additional observational studies.
• Maps findings across five predefined outcome domains: acute eGFR dip, chronic eGFR slope, proteinuria reduction, kidney outcomes, and mortality.

Limitations

• The dataset is a single 684.8 KB DOCX file, which is a small-scale textual summary rather than raw research data.
• Row count and column-level documentation are absent; the file contains a review manuscript.
• Mortality data specific to IgA nephropathy is noted as limited within the review.

Provenance

Source

figshare, author Atthaphong Phongphithakchai

Collection Method

Scoping review conducted according to PRISMA-ScR guidance, synthesizing existing randomized controlled trials and observational studies.

Freshness

Last updated 2026-04-30 04:16:15